| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prosthesis-Related Infections | 57 | 2021 | 175 | 14.170 |
Why?
|
| Defibrillators, Implantable | 52 | 2021 | 190 | 13.400 |
Why?
|
| Pacemaker, Artificial | 44 | 2020 | 173 | 10.960 |
Why?
|
| Endocarditis | 30 | 2022 | 106 | 7.560 |
Why?
|
| Endocarditis, Bacterial | 23 | 2022 | 134 | 6.750 |
Why?
|
| Bacteremia | 24 | 2022 | 407 | 6.300 |
Why?
|
| Staphylococcal Infections | 24 | 2021 | 562 | 5.140 |
Why?
|
| Anti-Bacterial Agents | 47 | 2024 | 2429 | 3.440 |
Why?
|
| Staphylococcus aureus | 12 | 2023 | 462 | 2.090 |
Why?
|
| Heart Valve Prosthesis | 5 | 2022 | 301 | 1.670 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 7 | 2023 | 221 | 1.660 |
Why?
|
| Bacterial Adhesion | 4 | 2020 | 105 | 1.590 |
Why?
|
| Humans | 175 | 2024 | 125439 | 1.570 |
Why?
|
| Aged | 79 | 2022 | 19739 | 1.570 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2017 | 147 | 1.520 |
Why?
|
| Device Removal | 19 | 2018 | 216 | 1.490 |
Why?
|
| Cross Infection | 4 | 2018 | 326 | 1.400 |
Why?
|
| Immunocompromised Host | 5 | 2019 | 294 | 1.380 |
Why?
|
| Male | 108 | 2024 | 61628 | 1.340 |
Why?
|
| Bacterial Infections | 6 | 2021 | 307 | 1.330 |
Why?
|
| Rhinoplasty | 2 | 2023 | 44 | 1.310 |
Why?
|
| Acinetobacter | 2 | 2020 | 7 | 1.280 |
Why?
|
| Equipment Contamination | 3 | 2020 | 37 | 1.250 |
Why?
|
| Gram-Positive Bacterial Infections | 6 | 2019 | 75 | 1.230 |
Why?
|
| Histoplasmosis | 3 | 2019 | 48 | 1.230 |
Why?
|
| Biofilms | 2 | 2020 | 88 | 1.210 |
Why?
|
| Middle Aged | 69 | 2024 | 26827 | 1.200 |
Why?
|
| Echocardiography, Transesophageal | 9 | 2021 | 240 | 1.200 |
Why?
|
| Heart-Assist Devices | 5 | 2019 | 1027 | 1.180 |
Why?
|
| Lyme Disease | 2 | 2019 | 35 | 1.170 |
Why?
|
| Antifungal Agents | 8 | 2019 | 291 | 1.150 |
Why?
|
| Positron Emission Tomography Computed Tomography | 2 | 2017 | 76 | 1.090 |
Why?
|
| Gram-Negative Bacteria | 3 | 2019 | 68 | 1.080 |
Why?
|
| Fever | 4 | 2019 | 300 | 1.030 |
Why?
|
| Cleft Lip | 2 | 2023 | 125 | 1.030 |
Why?
|
| Catheter-Related Infections | 2 | 2018 | 130 | 1.030 |
Why?
|
| Retrospective Studies | 52 | 2024 | 16362 | 1.010 |
Why?
|
| Adult | 51 | 2024 | 29635 | 0.990 |
Why?
|
| Kidney Failure, Chronic | 3 | 2022 | 886 | 0.990 |
Why?
|
| Female | 91 | 2024 | 66888 | 0.970 |
Why?
|
| Thiazoles | 2 | 2018 | 98 | 0.950 |
Why?
|
| Diarrhea | 2 | 2018 | 317 | 0.950 |
Why?
|
| Anti-Infective Agents | 5 | 2024 | 264 | 0.920 |
Why?
|
| Trametes | 1 | 2024 | 1 | 0.910 |
Why?
|
| Acinetobacter Infections | 3 | 2022 | 26 | 0.910 |
Why?
|
| Textiles | 1 | 2024 | 10 | 0.900 |
Why?
|
| Hospitalization | 9 | 2021 | 1792 | 0.890 |
Why?
|
| Antiviral Agents | 8 | 2021 | 767 | 0.890 |
Why?
|
| Antibiotic Prophylaxis | 4 | 2018 | 118 | 0.890 |
Why?
|
| Arrhythmias, Cardiac | 8 | 2020 | 459 | 0.880 |
Why?
|
| Surgical Wound Infection | 3 | 2020 | 259 | 0.880 |
Why?
|
| Decision Support Techniques | 3 | 2015 | 290 | 0.860 |
Why?
|
| Diagnostic Imaging | 3 | 2020 | 280 | 0.860 |
Why?
|
| Gentamicins | 3 | 2023 | 94 | 0.840 |
Why?
|
| Aged, 80 and over | 31 | 2021 | 6558 | 0.840 |
Why?
|
| Microbial Sensitivity Tests | 11 | 2022 | 798 | 0.820 |
Why?
|
| Mucormycosis | 3 | 2017 | 27 | 0.790 |
Why?
|
| Aspergillus fumigatus | 2 | 2017 | 43 | 0.790 |
Why?
|
| Risk Factors | 29 | 2021 | 10298 | 0.760 |
Why?
|
| Pakistan | 9 | 2022 | 81 | 0.730 |
Why?
|
| Psoas Abscess | 1 | 2021 | 3 | 0.730 |
Why?
|
| Actinobacteria | 1 | 2021 | 13 | 0.720 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2022 | 133 | 0.720 |
Why?
|
| Data Accuracy | 1 | 2020 | 25 | 0.690 |
Why?
|
| Polymyxins | 1 | 2020 | 15 | 0.690 |
Why?
|
| Transplant Recipients | 2 | 2019 | 217 | 0.690 |
Why?
|
| Frailty | 1 | 2022 | 105 | 0.690 |
Why?
|
| Spinal Cord Stimulation | 1 | 2020 | 10 | 0.680 |
Why?
|
| Renal Dialysis | 3 | 2022 | 862 | 0.680 |
Why?
|
| Wound Infection | 1 | 2020 | 53 | 0.680 |
Why?
|
| Xylenes | 1 | 2020 | 13 | 0.670 |
Why?
|
| beta-Lactam Resistance | 2 | 2017 | 47 | 0.670 |
Why?
|
| Radiopharmaceuticals | 2 | 2017 | 168 | 0.670 |
Why?
|
| Cellulitis | 2 | 2017 | 63 | 0.670 |
Why?
|
| Coated Materials, Biocompatible | 1 | 2020 | 38 | 0.660 |
Why?
|
| Community-Acquired Infections | 3 | 2018 | 241 | 0.650 |
Why?
|
| Pain | 3 | 2020 | 449 | 0.640 |
Why?
|
| Musculoskeletal Pain | 1 | 2019 | 14 | 0.640 |
Why?
|
| Anaplasmosis | 1 | 2019 | 2 | 0.640 |
Why?
|
| Clostridium Infections | 2 | 2014 | 245 | 0.640 |
Why?
|
| Myalgia | 1 | 2019 | 11 | 0.640 |
Why?
|
| Publishing | 1 | 2020 | 109 | 0.630 |
Why?
|
| Polymers | 1 | 2020 | 104 | 0.630 |
Why?
|
| Multimodal Imaging | 2 | 2020 | 114 | 0.630 |
Why?
|
| Cryptococcosis | 1 | 2019 | 42 | 0.620 |
Why?
|
| Gram-Positive Bacteria | 1 | 2019 | 47 | 0.620 |
Why?
|
| Minnesota | 11 | 2021 | 131 | 0.600 |
Why?
|
| Aircraft | 2 | 2011 | 20 | 0.600 |
Why?
|
| Adenoviridae Infections | 1 | 2018 | 71 | 0.600 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2020 | 164 | 0.600 |
Why?
|
| Invasive Fungal Infections | 1 | 2018 | 13 | 0.590 |
Why?
|
| Coronavirus Infections | 2 | 2020 | 362 | 0.590 |
Why?
|
| Enteritis | 1 | 2018 | 54 | 0.590 |
Why?
|
| Larynx | 1 | 2019 | 72 | 0.590 |
Why?
|
| Pneumonia, Viral | 2 | 2020 | 378 | 0.590 |
Why?
|
| Diagnosis, Differential | 10 | 2018 | 1899 | 0.580 |
Why?
|
| Postoperative Complications | 6 | 2019 | 3055 | 0.580 |
Why?
|
| Cost of Illness | 1 | 2020 | 253 | 0.580 |
Why?
|
| Borrelia burgdorferi | 1 | 2018 | 19 | 0.570 |
Why?
|
| Treatment Outcome | 26 | 2024 | 12303 | 0.570 |
Why?
|
| Cranial Nerve Diseases | 1 | 2018 | 26 | 0.570 |
Why?
|
| Heart Failure | 4 | 2022 | 2298 | 0.570 |
Why?
|
| Bartonella Infections | 1 | 2017 | 7 | 0.570 |
Why?
|
| Medicare | 3 | 2020 | 428 | 0.560 |
Why?
|
| Pulmonary Aspergillosis | 1 | 2017 | 11 | 0.560 |
Why?
|
| Bartonella henselae | 1 | 2017 | 20 | 0.560 |
Why?
|
| Shock, Septic | 1 | 2019 | 147 | 0.560 |
Why?
|
| Costal Cartilage | 1 | 2017 | 4 | 0.560 |
Why?
|
| Young Adult | 23 | 2024 | 9085 | 0.560 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2019 | 163 | 0.560 |
Why?
|
| Travel | 2 | 2011 | 115 | 0.560 |
Why?
|
| Triazoles | 2 | 2017 | 140 | 0.560 |
Why?
|
| Cardiologists | 1 | 2017 | 20 | 0.560 |
Why?
|
| Mediastinum | 1 | 2017 | 43 | 0.560 |
Why?
|
| Burns | 3 | 2024 | 77 | 0.560 |
Why?
|
| Herpes Zoster | 1 | 2017 | 23 | 0.560 |
Why?
|
| Firmicutes | 1 | 2017 | 21 | 0.550 |
Why?
|
| Nephritis, Interstitial | 1 | 2017 | 38 | 0.550 |
Why?
|
| Brain Abscess | 1 | 2017 | 50 | 0.540 |
Why?
|
| Fluoroquinolones | 1 | 2017 | 93 | 0.540 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 1173 | 0.540 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2019 | 113 | 0.540 |
Why?
|
| Hypokalemia | 1 | 2017 | 42 | 0.540 |
Why?
|
| Temporal Lobe | 1 | 2017 | 113 | 0.540 |
Why?
|
| Incidence | 13 | 2021 | 3135 | 0.530 |
Why?
|
| Fluorescein Angiography | 1 | 2017 | 138 | 0.530 |
Why?
|
| Sepsis | 1 | 2021 | 484 | 0.530 |
Why?
|
| Eye Infections, Bacterial | 1 | 2017 | 92 | 0.520 |
Why?
|
| Abdominal Pain | 3 | 2015 | 306 | 0.520 |
Why?
|
| Cardiovascular Infections | 3 | 2017 | 7 | 0.520 |
Why?
|
| Cardiac Resynchronization Therapy Devices | 2 | 2017 | 13 | 0.510 |
Why?
|
| Streptococcal Infections | 6 | 2021 | 241 | 0.510 |
Why?
|
| Coinfection | 2 | 2019 | 172 | 0.510 |
Why?
|
| Adenoviridae | 1 | 2018 | 605 | 0.500 |
Why?
|
| Arthroplasty | 1 | 2015 | 16 | 0.490 |
Why?
|
| Comorbidity | 10 | 2018 | 1532 | 0.490 |
Why?
|
| Vision Disorders | 1 | 2017 | 211 | 0.480 |
Why?
|
| Blood Culture | 3 | 2021 | 30 | 0.480 |
Why?
|
| Health Expenditures | 1 | 2016 | 103 | 0.480 |
Why?
|
| beta-Lactamases | 1 | 2017 | 198 | 0.480 |
Why?
|
| Virus Diseases | 1 | 2018 | 280 | 0.480 |
Why?
|
| Autoimmune Diseases | 1 | 2017 | 252 | 0.470 |
Why?
|
| Cytokines | 1 | 2020 | 1288 | 0.460 |
Why?
|
| Trichinella | 1 | 2014 | 2 | 0.450 |
Why?
|
| Population Surveillance | 5 | 2018 | 389 | 0.450 |
Why?
|
| Trichinellosis | 1 | 2014 | 14 | 0.450 |
Why?
|
| Propionibacterium | 2 | 2016 | 4 | 0.450 |
Why?
|
| Risk Assessment | 11 | 2019 | 3440 | 0.450 |
Why?
|
| Albendazole | 1 | 2014 | 29 | 0.450 |
Why?
|
| Clostridium | 1 | 2014 | 17 | 0.450 |
Why?
|
| Uterine Myomectomy | 1 | 2014 | 10 | 0.440 |
Why?
|
| Stroke | 1 | 2022 | 979 | 0.440 |
Why?
|
| Prostheses and Implants | 3 | 2020 | 152 | 0.440 |
Why?
|
| Gastrointestinal Hemorrhage | 2 | 2015 | 230 | 0.440 |
Why?
|
| Shiga-Toxigenic Escherichia coli | 1 | 2013 | 4 | 0.430 |
Why?
|
| Diabetic Angiopathies | 1 | 2014 | 65 | 0.430 |
Why?
|
| Albuminuria | 1 | 2014 | 103 | 0.430 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 2 | 2017 | 43 | 0.430 |
Why?
|
| Strongyloides stercoralis | 1 | 2013 | 23 | 0.430 |
Why?
|
| Haemophilus parainfluenzae | 1 | 2013 | 11 | 0.420 |
Why?
|
| Kidney Transplantation | 1 | 2019 | 651 | 0.420 |
Why?
|
| Bacterial Proteins | 2 | 2023 | 887 | 0.420 |
Why?
|
| Strongyloidiasis | 1 | 2013 | 43 | 0.420 |
Why?
|
| Immunosuppressive Agents | 1 | 2017 | 645 | 0.420 |
Why?
|
| Leiomyoma | 1 | 2014 | 81 | 0.420 |
Why?
|
| Follow-Up Studies | 14 | 2019 | 5174 | 0.410 |
Why?
|
| Cardiac Pacing, Artificial | 2 | 2020 | 118 | 0.410 |
Why?
|
| Embolism | 1 | 2013 | 46 | 0.410 |
Why?
|
| Haemophilus Infections | 1 | 2013 | 91 | 0.410 |
Why?
|
| Uterine Neoplasms | 1 | 2014 | 104 | 0.410 |
Why?
|
| Amphotericin B | 3 | 2019 | 90 | 0.400 |
Why?
|
| Osteomyelitis | 1 | 2015 | 209 | 0.400 |
Why?
|
| Pancytopenia | 1 | 2012 | 41 | 0.390 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2019 | 618 | 0.390 |
Why?
|
| Hypertension | 2 | 2020 | 1332 | 0.390 |
Why?
|
| Surgical Mesh | 3 | 2018 | 61 | 0.390 |
Why?
|
| Abscess | 4 | 2018 | 138 | 0.390 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2019 | 854 | 0.390 |
Why?
|
| Survival Rate | 9 | 2014 | 2050 | 0.380 |
Why?
|
| Herpesvirus 2, Human | 1 | 2011 | 14 | 0.380 |
Why?
|
| Herpes Genitalis | 1 | 2011 | 11 | 0.380 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2011 | 44 | 0.370 |
Why?
|
| Escherichia coli Infections | 1 | 2013 | 189 | 0.370 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 732 | 0.370 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2011 | 42 | 0.360 |
Why?
|
| RNA, Ribosomal, 16S | 3 | 2021 | 363 | 0.360 |
Why?
|
| Polymerase Chain Reaction | 3 | 2021 | 1587 | 0.360 |
Why?
|
| Cardiovascular Diseases | 3 | 2013 | 1960 | 0.350 |
Why?
|
| Ambulatory Surgical Procedures | 2 | 2016 | 56 | 0.350 |
Why?
|
| Pregnancy Complications, Infectious | 2 | 2014 | 456 | 0.350 |
Why?
|
| Miniaturization | 3 | 2020 | 26 | 0.340 |
Why?
|
| Safety | 1 | 2011 | 217 | 0.340 |
Why?
|
| Disease Management | 3 | 2020 | 532 | 0.340 |
Why?
|
| Brain Diseases | 1 | 2013 | 300 | 0.340 |
Why?
|
| Adolescent | 17 | 2021 | 19447 | 0.340 |
Why?
|
| Ultrasonography | 1 | 2015 | 939 | 0.330 |
Why?
|
| Nose | 2 | 2023 | 94 | 0.330 |
Why?
|
| Critical Care | 2 | 2014 | 656 | 0.330 |
Why?
|
| Viridans Streptococci | 3 | 2015 | 8 | 0.330 |
Why?
|
| United States | 13 | 2020 | 10924 | 0.320 |
Why?
|
| Disease Transmission, Infectious | 3 | 2021 | 84 | 0.320 |
Why?
|
| Ceftriaxone | 3 | 2018 | 67 | 0.320 |
Why?
|
| Vancomycin | 4 | 2022 | 217 | 0.320 |
Why?
|
| Carbapenems | 3 | 2022 | 36 | 0.310 |
Why?
|
| Time Factors | 10 | 2019 | 6324 | 0.310 |
Why?
|
| Length of Stay | 6 | 2024 | 1313 | 0.310 |
Why?
|
| Pandemics | 3 | 2021 | 1113 | 0.300 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2017 | 1122 | 0.300 |
Why?
|
| Clinical Laboratory Techniques | 2 | 2020 | 140 | 0.300 |
Why?
|
| Prosthesis Implantation | 3 | 2016 | 140 | 0.290 |
Why?
|
| Electrocardiography, Ambulatory | 2 | 2019 | 61 | 0.290 |
Why?
|
| Surgical Procedures, Operative | 2 | 2020 | 184 | 0.290 |
Why?
|
| Patient Satisfaction | 2 | 2024 | 475 | 0.280 |
Why?
|
| Infection Control | 2 | 2020 | 156 | 0.280 |
Why?
|
| Prospective Studies | 10 | 2020 | 6174 | 0.280 |
Why?
|
| Prognosis | 7 | 2020 | 4690 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2019 | 2091 | 0.280 |
Why?
|
| Leprosy, Lepromatous | 1 | 2007 | 2 | 0.280 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 649 | 0.270 |
Why?
|
| Bacteria | 2 | 2020 | 481 | 0.260 |
Why?
|
| Cohort Studies | 12 | 2021 | 4843 | 0.260 |
Why?
|
| Nitro Compounds | 2 | 2018 | 18 | 0.250 |
Why?
|
| Cross-Sectional Studies | 4 | 2022 | 3433 | 0.250 |
Why?
|
| Odds Ratio | 3 | 2014 | 1253 | 0.250 |
Why?
|
| Coccidioides | 1 | 2005 | 2 | 0.250 |
Why?
|
| Infant, Newborn | 8 | 2017 | 8268 | 0.250 |
Why?
|
| Coccidioidomycosis | 1 | 2005 | 12 | 0.240 |
Why?
|
| Male Urogenital Diseases | 1 | 2005 | 15 | 0.240 |
Why?
|
| Prosthesis Failure | 2 | 2017 | 156 | 0.240 |
Why?
|
| Echocardiography | 4 | 2021 | 1062 | 0.240 |
Why?
|
| Drug Administration Schedule | 2 | 2018 | 730 | 0.240 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 85 | 0.230 |
Why?
|
| Multivariate Analysis | 4 | 2014 | 1430 | 0.230 |
Why?
|
| Waste Disposal, Fluid | 1 | 2024 | 7 | 0.230 |
Why?
|
| Nontuberculous Mycobacteria | 1 | 2004 | 25 | 0.230 |
Why?
|
| Pneumonia | 3 | 2021 | 325 | 0.230 |
Why?
|
| Abdominal Abscess | 1 | 2004 | 25 | 0.220 |
Why?
|
| Injections, Intra-Articular | 1 | 2004 | 26 | 0.220 |
Why?
|
| Skin Transplantation | 1 | 2024 | 60 | 0.220 |
Why?
|
| Parents | 1 | 2011 | 1023 | 0.220 |
Why?
|
| Zea mays | 1 | 2024 | 43 | 0.220 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2021 | 292 | 0.220 |
Why?
|
| Salmonella typhi | 1 | 2024 | 17 | 0.220 |
Why?
|
| Aspergillosis | 1 | 2004 | 43 | 0.220 |
Why?
|
| Triamcinolone Acetonide | 1 | 2004 | 36 | 0.220 |
Why?
|
| Typhoid Fever | 1 | 2024 | 20 | 0.220 |
Why?
|
| Hernia, Inguinal | 1 | 2004 | 42 | 0.220 |
Why?
|
| Water Pollutants, Chemical | 1 | 2024 | 23 | 0.220 |
Why?
|
| Bandages | 1 | 2024 | 56 | 0.220 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2004 | 46 | 0.220 |
Why?
|
| Shoulder Joint | 1 | 2004 | 26 | 0.220 |
Why?
|
| Transplantation, Autologous | 1 | 2024 | 272 | 0.220 |
Why?
|
| Electronics | 2 | 2020 | 43 | 0.220 |
Why?
|
| Prevalence | 6 | 2017 | 2469 | 0.220 |
Why?
|
| Fluconazole | 2 | 2019 | 48 | 0.220 |
Why?
|
| Meningoencephalitis | 1 | 2003 | 17 | 0.210 |
Why?
|
| Arthritis, Infectious | 1 | 2004 | 59 | 0.210 |
Why?
|
| Pyoderma | 1 | 2023 | 2 | 0.210 |
Why?
|
| Esthetics, Dental | 1 | 2023 | 15 | 0.210 |
Why?
|
| Guideline Adherence | 2 | 2017 | 375 | 0.210 |
Why?
|
| Nasal Septum | 1 | 2023 | 17 | 0.210 |
Why?
|
| Hospital Mortality | 6 | 2017 | 1027 | 0.210 |
Why?
|
| Cartilage | 1 | 2023 | 48 | 0.210 |
Why?
|
| Ampicillin | 2 | 2024 | 56 | 0.200 |
Why?
|
| Ciprofloxacin | 2 | 2023 | 65 | 0.200 |
Why?
|
| Burn Units | 1 | 2022 | 7 | 0.200 |
Why?
|
| Hand Strength | 1 | 2022 | 39 | 0.200 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2017 | 316 | 0.200 |
Why?
|
| American Heart Association | 3 | 2015 | 322 | 0.200 |
Why?
|
| Reproducibility of Results | 3 | 2021 | 2904 | 0.200 |
Why?
|
| Inpatients | 2 | 2017 | 501 | 0.190 |
Why?
|
| Logistic Models | 3 | 2014 | 1808 | 0.190 |
Why?
|
| Confidence Intervals | 2 | 2013 | 283 | 0.190 |
Why?
|
| West Nile Fever | 1 | 2003 | 139 | 0.190 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.180 |
Why?
|
| Heart Valves | 2 | 2019 | 51 | 0.180 |
Why?
|
| Drug Resistance, Bacterial | 3 | 2024 | 365 | 0.180 |
Why?
|
| Practice Guidelines as Topic | 4 | 2015 | 1272 | 0.180 |
Why?
|
| Myoclonus | 1 | 2021 | 32 | 0.180 |
Why?
|
| Heparin | 1 | 2022 | 216 | 0.180 |
Why?
|
| Acinetobacter baumannii | 1 | 2022 | 37 | 0.180 |
Why?
|
| Cardiac Catheterization | 1 | 2005 | 632 | 0.180 |
Why?
|
| Staphylococcus | 1 | 2021 | 69 | 0.180 |
Why?
|
| Velopharyngeal Insufficiency | 1 | 2021 | 18 | 0.180 |
Why?
|
| Rifampin | 2 | 2023 | 131 | 0.180 |
Why?
|
| Hydroxychloroquine | 1 | 2021 | 17 | 0.180 |
Why?
|
| Spirochaetales | 1 | 2020 | 6 | 0.180 |
Why?
|
| Chloroquine | 1 | 2021 | 31 | 0.180 |
Why?
|
| Tertiary Care Centers | 1 | 2022 | 237 | 0.180 |
Why?
|
| Treponema pallidum | 1 | 2020 | 50 | 0.180 |
Why?
|
| Acellular Dermis | 1 | 2020 | 6 | 0.170 |
Why?
|
| Wound Healing | 1 | 2024 | 459 | 0.170 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2020 | 21 | 0.170 |
Why?
|
| Wettability | 1 | 2020 | 2 | 0.170 |
Why?
|
| Breast Implants | 1 | 2020 | 29 | 0.170 |
Why?
|
| Physicians' Offices | 1 | 2020 | 10 | 0.170 |
Why?
|
| Surgery Department, Hospital | 1 | 2020 | 20 | 0.170 |
Why?
|
| Sensitivity and Specificity | 4 | 2020 | 2057 | 0.170 |
Why?
|
| Voriconazole | 2 | 2014 | 34 | 0.170 |
Why?
|
| Child | 7 | 2021 | 24606 | 0.170 |
Why?
|
| Spine | 1 | 2021 | 142 | 0.170 |
Why?
|
| Facial Recognition | 1 | 2020 | 6 | 0.170 |
Why?
|
| Operative Time | 2 | 2019 | 165 | 0.170 |
Why?
|
| Encephalitis | 1 | 2021 | 109 | 0.170 |
Why?
|
| Materials Testing | 1 | 2020 | 72 | 0.170 |
Why?
|
| Betacoronavirus | 2 | 2020 | 291 | 0.170 |
Why?
|
| Cattle | 1 | 2021 | 567 | 0.170 |
Why?
|
| Syphilis | 1 | 2020 | 97 | 0.170 |
Why?
|
| Colony Count, Microbial | 1 | 2020 | 88 | 0.170 |
Why?
|
| Enterococcus faecalis | 2 | 2018 | 47 | 0.170 |
Why?
|
| Facial Expression | 1 | 2020 | 27 | 0.170 |
Why?
|
| Splenic Infarction | 1 | 2019 | 4 | 0.160 |
Why?
|
| Sex Distribution | 2 | 2013 | 305 | 0.160 |
Why?
|
| Carnobacteriaceae | 1 | 2019 | 2 | 0.160 |
Why?
|
| Pregnancy Outcome | 2 | 2014 | 595 | 0.160 |
Why?
|
| Mammaplasty | 1 | 2020 | 53 | 0.160 |
Why?
|
| Disease Vectors | 1 | 2019 | 24 | 0.160 |
Why?
|
| Age Distribution | 2 | 2013 | 417 | 0.160 |
Why?
|
| Enterococcus | 1 | 2019 | 29 | 0.160 |
Why?
|
| Transducers | 1 | 2019 | 24 | 0.160 |
Why?
|
| Itraconazole | 1 | 2019 | 25 | 0.160 |
Why?
|
| Flucytosine | 1 | 2019 | 17 | 0.160 |
Why?
|
| Histoplasma | 1 | 2019 | 31 | 0.160 |
Why?
|
| Cryptococcus neoformans | 1 | 2019 | 21 | 0.160 |
Why?
|
| Cleft Palate | 1 | 2021 | 142 | 0.160 |
Why?
|
| Wireless Technology | 1 | 2019 | 11 | 0.160 |
Why?
|
| Immunocompetence | 1 | 2019 | 33 | 0.160 |
Why?
|
| Rejuvenation | 1 | 2019 | 10 | 0.160 |
Why?
|
| Sonication | 1 | 2018 | 8 | 0.160 |
Why?
|
| Health Resources | 1 | 2020 | 116 | 0.160 |
Why?
|
| Cicatrix, Hypertrophic | 1 | 2019 | 6 | 0.160 |
Why?
|
| Heart Conduction System | 1 | 2020 | 148 | 0.160 |
Why?
|
| Rabbits | 1 | 2020 | 717 | 0.160 |
Why?
|
| Intra-Aortic Balloon Pumping | 1 | 2019 | 42 | 0.150 |
Why?
|
| Pelvic Infection | 1 | 2018 | 4 | 0.150 |
Why?
|
| Facial Injuries | 1 | 2019 | 22 | 0.150 |
Why?
|
| Metagenomics | 1 | 2019 | 102 | 0.150 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2020 | 225 | 0.150 |
Why?
|
| Extracellular Matrix | 1 | 2020 | 238 | 0.150 |
Why?
|
| Viral Load | 1 | 2020 | 388 | 0.150 |
Why?
|
| Spinal Cord | 1 | 2020 | 305 | 0.150 |
Why?
|
| Doxycycline | 1 | 2019 | 117 | 0.150 |
Why?
|
| Animals | 7 | 2021 | 34310 | 0.150 |
Why?
|
| Pain Management | 1 | 2020 | 177 | 0.150 |
Why?
|
| Peritonitis | 1 | 2018 | 78 | 0.150 |
Why?
|
| Public Health Surveillance | 1 | 2018 | 38 | 0.150 |
Why?
|
| Rhizomucor | 1 | 2017 | 1 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2020 | 372 | 0.140 |
Why?
|
| Genes, Bacterial | 1 | 2018 | 210 | 0.140 |
Why?
|
| Cardiac Electrophysiology | 1 | 2017 | 10 | 0.140 |
Why?
|
| Aortic Valve | 2 | 2020 | 442 | 0.140 |
Why?
|
| Periodicals as Topic | 1 | 2020 | 197 | 0.140 |
Why?
|
| Equipment and Supplies | 1 | 2017 | 25 | 0.140 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2017 | 9 | 0.140 |
Why?
|
| Recurrence | 4 | 2018 | 1394 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2018 | 94 | 0.140 |
Why?
|
| Fundus Oculi | 1 | 2017 | 64 | 0.140 |
Why?
|
| Minocycline | 1 | 2017 | 38 | 0.140 |
Why?
|
| Mediastinal Neoplasms | 1 | 2017 | 43 | 0.140 |
Why?
|
| Suction | 1 | 2017 | 55 | 0.140 |
Why?
|
| Emotions | 1 | 2020 | 358 | 0.140 |
Why?
|
| Analysis of Variance | 2 | 2011 | 1019 | 0.140 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2017 | 29 | 0.140 |
Why?
|
| Candida | 1 | 2017 | 75 | 0.140 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 313 | 0.130 |
Why?
|
| Steroids | 2 | 2021 | 202 | 0.130 |
Why?
|
| Electronic Health Records | 3 | 2018 | 724 | 0.130 |
Why?
|
| Injections | 1 | 2017 | 155 | 0.130 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 245 | 0.130 |
Why?
|
| Opportunistic Infections | 1 | 2017 | 79 | 0.130 |
Why?
|
| Area Under Curve | 2 | 2014 | 318 | 0.130 |
Why?
|
| Memory | 1 | 2020 | 359 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2018 | 185 | 0.130 |
Why?
|
| Vibrio cholerae non-O1 | 1 | 2016 | 1 | 0.130 |
Why?
|
| Actinomycetales Infections | 1 | 2016 | 12 | 0.130 |
Why?
|
| Global Health | 1 | 2021 | 568 | 0.130 |
Why?
|
| Vibrio Infections | 1 | 2016 | 16 | 0.130 |
Why?
|
| Enterobacteriaceae | 1 | 2016 | 35 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 177 | 0.130 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2016 | 54 | 0.130 |
Why?
|
| Mycoses | 1 | 2017 | 118 | 0.120 |
Why?
|
| Stem Cell Transplantation | 1 | 2017 | 233 | 0.120 |
Why?
|
| Adipose Tissue | 1 | 2019 | 465 | 0.120 |
Why?
|
| Case-Control Studies | 3 | 2019 | 3310 | 0.120 |
Why?
|
| Debridement | 2 | 2007 | 89 | 0.120 |
Why?
|
| Lower Extremity | 1 | 2017 | 178 | 0.120 |
Why?
|
| Mitral Valve Prolapse | 1 | 2015 | 28 | 0.120 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2017 | 137 | 0.120 |
Why?
|
| Attitude of Health Personnel | 2 | 2019 | 675 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2018 | 274 | 0.120 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2015 | 18 | 0.120 |
Why?
|
| Stem Cells | 1 | 2020 | 709 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 2 | 2019 | 1763 | 0.120 |
Why?
|
| Acute Disease | 1 | 2017 | 1096 | 0.110 |
Why?
|
| Pulmonary Valve | 1 | 2015 | 92 | 0.110 |
Why?
|
| Urologic Surgical Procedures | 1 | 2014 | 57 | 0.110 |
Why?
|
| Echinocandins | 1 | 2014 | 44 | 0.110 |
Why?
|
| Endoscopy | 1 | 2016 | 280 | 0.110 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2015 | 117 | 0.110 |
Why?
|
| Foreign-Body Migration | 1 | 2014 | 70 | 0.110 |
Why?
|
| Positron-Emission Tomography | 1 | 2016 | 306 | 0.110 |
Why?
|
| Algorithms | 3 | 2020 | 1633 | 0.110 |
Why?
|
| Chloramphenicol | 2 | 2024 | 28 | 0.110 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2021 | 730 | 0.110 |
Why?
|
| Kidney Function Tests | 1 | 2014 | 130 | 0.110 |
Why?
|
| Ureteral Obstruction | 1 | 2014 | 105 | 0.110 |
Why?
|
| Florida | 1 | 2013 | 78 | 0.110 |
Why?
|
| Rare Diseases | 1 | 2015 | 190 | 0.110 |
Why?
|
| Spinal Cord Injuries | 1 | 2016 | 313 | 0.110 |
Why?
|
| Causality | 1 | 2013 | 84 | 0.110 |
Why?
|
| Electrodes, Implanted | 1 | 2014 | 168 | 0.110 |
Why?
|
| Pregnancy Complications, Cardiovascular | 1 | 2014 | 104 | 0.110 |
Why?
|
| ROC Curve | 1 | 2014 | 572 | 0.100 |
Why?
|
| Severity of Illness Index | 2 | 2014 | 2912 | 0.100 |
Why?
|
| Reoperation | 2 | 2017 | 830 | 0.100 |
Why?
|
| Furunculosis | 1 | 2012 | 4 | 0.100 |
Why?
|
| Chills | 1 | 2012 | 6 | 0.100 |
Why?
|
| Patient Discharge | 1 | 2016 | 497 | 0.100 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2017 | 435 | 0.100 |
Why?
|
| Urinary Tract Infections | 1 | 2016 | 300 | 0.100 |
Why?
|
| Seizures | 1 | 2017 | 871 | 0.100 |
Why?
|
| Kidney | 1 | 2019 | 1363 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 824 | 0.100 |
Why?
|
| Morbidity | 3 | 2020 | 248 | 0.100 |
Why?
|
| Acyclovir | 1 | 2011 | 45 | 0.090 |
Why?
|
| Gastrointestinal Diseases | 1 | 2015 | 338 | 0.090 |
Why?
|
| Heart Diseases | 1 | 2016 | 496 | 0.090 |
Why?
|
| Spinal Diseases | 1 | 2011 | 45 | 0.090 |
Why?
|
| Exanthema | 1 | 2012 | 71 | 0.090 |
Why?
|
| Valine | 1 | 2011 | 116 | 0.090 |
Why?
|
| Disease Outbreaks | 1 | 2013 | 320 | 0.090 |
Why?
|
| Lipids | 1 | 2015 | 522 | 0.090 |
Why?
|
| Blood-Borne Pathogens | 1 | 2011 | 3 | 0.090 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 239 | 0.090 |
Why?
|
| Child, Preschool | 3 | 2019 | 14142 | 0.090 |
Why?
|
| Metronidazole | 1 | 2011 | 154 | 0.090 |
Why?
|
| Intensive Care Units | 1 | 2014 | 493 | 0.090 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 303 | 0.090 |
Why?
|
| Costs and Cost Analysis | 1 | 2011 | 163 | 0.090 |
Why?
|
| Gram-Positive Cocci | 1 | 2010 | 2 | 0.090 |
Why?
|
| Aspirin | 1 | 2012 | 222 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2012 | 1361 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2019 | 1043 | 0.090 |
Why?
|
| Health Planning Guidelines | 1 | 2010 | 32 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1692 | 0.090 |
Why?
|
| Respiratory Syncytial Virus Infections | 1 | 2013 | 345 | 0.080 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 4405 | 0.080 |
Why?
|
| Infant | 2 | 2017 | 12597 | 0.080 |
Why?
|
| Age of Onset | 1 | 2011 | 601 | 0.080 |
Why?
|
| Myocarditis | 1 | 2010 | 130 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2013 | 509 | 0.080 |
Why?
|
| Case Management | 1 | 2009 | 20 | 0.080 |
Why?
|
| Academic Medical Centers | 1 | 2011 | 309 | 0.080 |
Why?
|
| Smoking | 1 | 2015 | 1049 | 0.080 |
Why?
|
| Biomarkers | 1 | 2018 | 3104 | 0.080 |
Why?
|
| DNA, Bacterial | 2 | 2021 | 475 | 0.080 |
Why?
|
| Phenotype | 1 | 2018 | 4269 | 0.070 |
Why?
|
| Pregnancy | 3 | 2014 | 7222 | 0.070 |
Why?
|
| Stents | 1 | 2014 | 834 | 0.070 |
Why?
|
| Ecthyma, Contagious | 1 | 2008 | 1 | 0.070 |
Why?
|
| Poxviridae | 1 | 2008 | 4 | 0.070 |
Why?
|
| Sheep Diseases | 1 | 2008 | 7 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2020 | 2519 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2011 | 385 | 0.070 |
Why?
|
| Skin Diseases, Infectious | 1 | 2008 | 24 | 0.070 |
Why?
|
| Zoonoses | 1 | 2008 | 44 | 0.070 |
Why?
|
| Equipment Design | 2 | 2020 | 589 | 0.070 |
Why?
|
| Survival Analysis | 3 | 2017 | 1494 | 0.070 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 3743 | 0.070 |
Why?
|
| Sheep | 1 | 2008 | 220 | 0.070 |
Why?
|
| Probability | 1 | 2007 | 318 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 1 | 2007 | 234 | 0.070 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 86 | 0.060 |
Why?
|
| Urogenital System | 1 | 2005 | 34 | 0.060 |
Why?
|
| Lung Diseases, Fungal | 1 | 2005 | 32 | 0.060 |
Why?
|
| Corynebacterium Infections | 1 | 2005 | 4 | 0.060 |
Why?
|
| Motion Sickness | 1 | 2005 | 11 | 0.060 |
Why?
|
| Respiration, Artificial | 2 | 2021 | 473 | 0.060 |
Why?
|
| Patient Safety | 2 | 2020 | 398 | 0.060 |
Why?
|
| Sudden Infant Death | 1 | 2005 | 32 | 0.060 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2005 | 37 | 0.060 |
Why?
|
| RNA, Viral | 2 | 2022 | 538 | 0.060 |
Why?
|
| Body Surface Area | 1 | 2024 | 31 | 0.060 |
Why?
|
| Shoulder Injuries | 1 | 2004 | 6 | 0.060 |
Why?
|
| Registries | 3 | 2018 | 1434 | 0.060 |
Why?
|
| Paralysis | 1 | 2003 | 35 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 1174 | 0.050 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2013 | 1271 | 0.050 |
Why?
|
| Cefoxitin | 1 | 2023 | 5 | 0.050 |
Why?
|
| Linezolid | 1 | 2023 | 25 | 0.050 |
Why?
|
| Erythromycin | 1 | 2023 | 20 | 0.050 |
Why?
|
| Clindamycin | 1 | 2023 | 40 | 0.050 |
Why?
|
| Electromyography | 1 | 2003 | 163 | 0.050 |
Why?
|
| Electrophysiology | 1 | 2003 | 272 | 0.050 |
Why?
|
| Risk | 1 | 2005 | 759 | 0.050 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2005 | 95 | 0.050 |
Why?
|
| Hypersensitivity | 1 | 2005 | 185 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2021 | 1119 | 0.050 |
Why?
|
| Exodeoxyribonucleases | 1 | 2022 | 51 | 0.050 |
Why?
|
| Copper | 1 | 2022 | 63 | 0.050 |
Why?
|
| Serum Albumin | 1 | 2022 | 113 | 0.050 |
Why?
|
| Genes, rRNA | 1 | 2021 | 19 | 0.050 |
Why?
|
| Vegetables | 1 | 2024 | 262 | 0.050 |
Why?
|
| Colistin | 1 | 2022 | 30 | 0.050 |
Why?
|
| Age Factors | 2 | 2021 | 2828 | 0.050 |
Why?
|
| Chi-Square Distribution | 2 | 2013 | 586 | 0.050 |
Why?
|
| Oxygen | 1 | 2005 | 556 | 0.050 |
Why?
|
| Palate, Soft | 1 | 2021 | 16 | 0.050 |
Why?
|
| Infectious Disease Incubation Period | 1 | 2021 | 7 | 0.050 |
Why?
|
| Air Microbiology | 1 | 2021 | 11 | 0.050 |
Why?
|
| Polymyxin B | 1 | 2022 | 47 | 0.050 |
Why?
|
| Speech Disorders | 1 | 2021 | 43 | 0.040 |
Why?
|
| Pyrimidines | 1 | 2004 | 377 | 0.040 |
Why?
|
| Azithromycin | 1 | 2021 | 43 | 0.040 |
Why?
|
| Speech | 1 | 2021 | 62 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2021 | 120 | 0.040 |
Why?
|
| Symptom Assessment | 1 | 2021 | 101 | 0.040 |
Why?
|
| Mastectomy | 1 | 2020 | 64 | 0.040 |
Why?
|
| Acute Lung Injury | 1 | 2021 | 63 | 0.040 |
Why?
|
| Thrombosis | 1 | 2005 | 520 | 0.040 |
Why?
|
| Penicillins | 1 | 2020 | 154 | 0.040 |
Why?
|
| CRISPR-Cas Systems | 1 | 2022 | 257 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2021 | 173 | 0.040 |
Why?
|
| Genes, Mitochondrial | 1 | 2019 | 17 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2020 | 130 | 0.040 |
Why?
|
| Primary Prevention | 1 | 2021 | 172 | 0.040 |
Why?
|
| Hypoxia | 1 | 2021 | 248 | 0.040 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2020 | 223 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2021 | 203 | 0.040 |
Why?
|
| Australia | 1 | 2019 | 140 | 0.040 |
Why?
|
| Injections, Intralesional | 1 | 2019 | 48 | 0.040 |
Why?
|
| Esthetics | 1 | 2019 | 37 | 0.040 |
Why?
|
| Tuberculosis | 1 | 2005 | 527 | 0.040 |
Why?
|
| Abdomen, Acute | 1 | 2018 | 14 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2021 | 319 | 0.040 |
Why?
|
| Species Specificity | 1 | 2019 | 551 | 0.040 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2019 | 37 | 0.040 |
Why?
|
| Workflow | 1 | 2019 | 118 | 0.040 |
Why?
|
| Canada | 1 | 2019 | 286 | 0.040 |
Why?
|
| Europe | 1 | 2019 | 359 | 0.040 |
Why?
|
| Injury Severity Score | 1 | 2019 | 225 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2022 | 578 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 3603 | 0.040 |
Why?
|
| Cardiology Service, Hospital | 1 | 2017 | 15 | 0.040 |
Why?
|
| United Kingdom | 1 | 2018 | 190 | 0.030 |
Why?
|
| Phylogeny | 1 | 2019 | 687 | 0.030 |
Why?
|
| Sex Factors | 1 | 2021 | 1282 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2017 | 109 | 0.030 |
Why?
|
| Retreatment | 1 | 2017 | 89 | 0.030 |
Why?
|
| Drainage | 1 | 2018 | 260 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2018 | 338 | 0.030 |
Why?
|
| Electrophysiological Phenomena | 1 | 2017 | 66 | 0.030 |
Why?
|
| DNA | 1 | 2022 | 1619 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 222 | 0.030 |
Why?
|
| Hematoma | 1 | 2017 | 91 | 0.030 |
Why?
|
| Mortality | 1 | 2018 | 238 | 0.030 |
Why?
|
| Patient Education as Topic | 1 | 2019 | 446 | 0.030 |
Why?
|
| Serotyping | 1 | 2016 | 178 | 0.030 |
Why?
|
| Environment | 1 | 2016 | 144 | 0.030 |
Why?
|
| Streptococcus | 1 | 2016 | 60 | 0.030 |
Why?
|
| Bacterial Typing Techniques | 1 | 2016 | 99 | 0.030 |
Why?
|
| Patient Preference | 1 | 2016 | 118 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 2018 | 511 | 0.030 |
Why?
|
| Ureteroscopy | 1 | 2014 | 17 | 0.030 |
Why?
|
| Resuscitation Orders | 1 | 2014 | 32 | 0.030 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2016 | 172 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2014 | 38 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2016 | 203 | 0.030 |
Why?
|
| Peripartum Period | 1 | 2014 | 28 | 0.030 |
Why?
|
| Rheumatic Heart Disease | 1 | 2014 | 38 | 0.030 |
Why?
|
| Fungi | 1 | 2014 | 69 | 0.030 |
Why?
|
| Maternal Mortality | 1 | 2014 | 79 | 0.030 |
Why?
|
| Palivizumab | 1 | 2013 | 47 | 0.030 |
Why?
|
| Ureter | 1 | 2014 | 94 | 0.030 |
Why?
|
| Organ Transplantation | 1 | 2015 | 168 | 0.030 |
Why?
|
| Urinary Bladder | 1 | 2014 | 244 | 0.030 |
Why?
|
| Infant Mortality | 1 | 2014 | 174 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2014 | 267 | 0.030 |
Why?
|
| Sweating | 1 | 2012 | 7 | 0.030 |
Why?
|
| Infant, Low Birth Weight | 1 | 2013 | 167 | 0.020 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2013 | 147 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2015 | 277 | 0.020 |
Why?
|
| Radiography | 1 | 2014 | 809 | 0.020 |
Why?
|
| Drug Resistance, Microbial | 1 | 2012 | 194 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2012 | 366 | 0.020 |
Why?
|
| Leukocytes | 1 | 2012 | 212 | 0.020 |
Why?
|
| Drug Implants | 1 | 2010 | 42 | 0.020 |
Why?
|
| New York | 1 | 2010 | 68 | 0.020 |
Why?
|
| Infusions, Intravenous | 1 | 2012 | 554 | 0.020 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2012 | 265 | 0.020 |
Why?
|
| Critical Illness | 1 | 2014 | 601 | 0.020 |
Why?
|
| United Arab Emirates | 1 | 2008 | 1 | 0.020 |
Why?
|
| Quality of Life | 1 | 2018 | 1949 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 2183 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2008 | 63 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2008 | 478 | 0.020 |
Why?
|
| Monocytes | 1 | 2008 | 345 | 0.020 |
Why?
|
| Electrocardiography | 1 | 2010 | 977 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 3109 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2008 | 3897 | 0.010 |
Why?
|
| Heart Defects, Congenital | 1 | 2014 | 1830 | 0.010 |
Why?
|